Ephion Health Raises €300,000 and Plans the Launch to Germany, France, and the UK

Ephion Health raises capital to grow abroad. The spin-off of the Sant Joan de Déu Hospital in Barcelona and the Eurecat Technology Center has raised €300,000 in a round of financing, while preparing to transfer its technology to Germany, France, and the United Kingdom, as stated by Quique Llaudet, CEO of the company.

The Spanish company applies artificial intelligence (AI) to detect new biomarkers and measure the health status of chronic patients. Its first product, Ephion Mobility, monitors rare diseases such as Duchenne Muscular Dystrophy.

Ephion’s technology allows the integration of data from different commercial wearables while the patient walks just ten meters. These data are combined with questionnaires and clinical scales to be analyzed by AI algorithms and generate a clinically validated biomarker that accurately and sensitively quantifies the patient’s condition.

If you want to read more about Ephion Health and find the most important financial news of the day, download for free our companion app Born2Invest.

Ephion Health will reach €100,000 in 2023, but its billing will skyrocket in 2024

The Ephion Health solution is a software-based medical device offered to hospitals to monitor chronic patients, in a hospital or remotely, and make scientific evidence available to doctors to support clinical and pharmaceutical decision-making. , to demonstrate the efficacy of drugs in clinical trials with new digital biomarkers.

To date, Ephion has agreements with five hospitals for the implementation of its Ephion Mobility technology in neuromuscular diseases: the Sant Joan de Deu Hospital, the Vall d’Hebrón Hospital, the 12 de Octubre Hospital, the Virgen Macarena Hospital, and the La Faith; while studying its entry into Germany, the United Kingdom, and France. 

Now, Ephion wants to expand its portfolio and is already working on new products. Firstly, it has reached an agreement with Quironsalud to transfer its technology to the Sagrat Cor residence in Barcelona, ​​where it monitors elderly patients and quantifies the risk of falls that awaits them. Likewise, Ephion is finalizing a new product in the segment of heart failure, respiratory failure, and stroke.

Ephion wants to expand its portfolio and is already working on new products

The funds raised so far allow Ephion to “commercialize the first product and continue developing our portfolio during the next year,” according to Llaudet. This year the group will reach close to €100,000, which next year, with the jump to Europe, will increase to one million euros. The company anticipates that this billing will continue to climb as the company’s product portfolio increases.

Ephion is led by its CEO Quique Llaudet,  an Organic Chemist from the Sarrià Chemical Institute, a Ph.D. in Biology from the University of Warwick (United Kingdom), and an MBA from Iese. Mireia Claramunt is the director of technology, a master’s degree in Biomedical Engineering from the University of Barcelona (UB) and the Polytechnic University of Catalonia (UPC), while Sebastián Idelsohn, a Mechanical Engineer from the National University of Rosario (Argentina) and doctor in Biomechanics by the UPC.

__

(Featured image by  geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.